Home > Insider Trading > Filing (0001209191-17-012985)

Filing Details

Accession Number:: 0001209191-17-012985
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-02-21 20:19:05
Reporting Period:: 2017-02-16

Filing Date:: 2017-02-21
Accepted Time:: 2017-02-21 20:19:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1142750	Amn Healthcare Services Inc	AMN	Services-Help Supply Services (7363)	061500476

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1410701	Ralph Henderson	12400 High Bluff Drive San Diego CA 92130	Pres., Prof. Svc. & Staffing	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-02-16	17,574	$0.00	59,095	No	4	A	Direct
Common Stock	Disposition	2017-02-16	9,170	$38.88	49,925	No	4	F	Direct
Common Stock	Acquisiton	2017-02-16	3,058	$0.00	52,983	No	4	M	Direct
Common Stock	Disposition	2017-02-16	1,595	$38.88	51,388	No	4	F	Direct
Common Stock	Acquisiton	2017-02-16	2,296	$0.00	53,684	No	4	M	Direct
Common Stock	Disposition	2017-02-16	1,198	$38.88	52,486	No	4	F	Direct
Common Stock	Disposition	2017-02-16	3,249	$40.00	49,237	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	F	Direct
No	4	M	Direct
No	4	F	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2017-02-16	3,058	$0.00	3,058	$0.00
Common Stock	Restricted Stock Units	Disposition	2017-02-16	2,296	$0.00	2,296	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,969			No	4	M	Direct
4,662			No	4	M	Direct

Footnotes

The acquisition of Common Stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 3, 2014. The ultimate number of PRSUs that could have been earned and vested under this award depended on the Company achieving or exceeding, on a consolidated basis, a certain specified adjusted earnings before interest, taxes, depreciation and amortization, divided by gross revenue and expressed as a percentage ("Adjusted EBITDA Margin") as of December 31, 2016 for the one-year period beginning on January 1, 2016 and ended December 31, 2016. The maximum amount of PRSUs for this award were deemed earned and vested.
Number of shares withheld for tax purposes.
Common Stock acquired on the vesting of Restricted Stock Units ("RSUs").
Common Stock acquired on the vesting of RSUs.
The sale of 3,249 shares of Common Stock reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The RSUs identified in this row were granted pursuant to the AMN Healthcare Equity Plan. Each RSU represents a contingent right to receive one share of Common Stock.
The RSUs identified in this row were granted on January 5, 2015 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization (EBITDA) target for the 2015 fiscal year and on the second anniversary of the grant date, in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2016 fiscal year.
RSUs do not have an expiration date.
The RSUs identified in this row were granted on January 5, 2016 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization (EBITDA) target for the 2016 fiscal year and on the second anniversary of the grant date, in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2017 fiscal year.